An in Vivo Approach for Globally Estimating the Drug Flow between Blood and Tissue for Nafamostat Mesilate: the Main Hydrolysis Site Determination in Human

Abstract

Nafamostat mesilate, an ester drug with extensive hydrolysis in vivo, exhibits species difference in the relative contribution for its hydrolysis in blood and tissues. For the rat, the main hydrolysis site may be blood and human may be tissue (mainly by liver). The paper gave in vivo evidence that human tissue may give more contribution for its hydrolysis. In the initial phase of drug administration, the drug accumulating level in tissue was low; the efflux fraction from tissue into blood can be ignorable comparing with the drug influx into tissue. Based on urine and plasma metabolite analysis, we concluded that in the initial phase almost all the drug hydrolysis in blood was excreted into urine. Then according to the initial urine metabolite analysis, we can estimate the drug hydrolysis rate in blood. The rate of drug diffusion from blood into tissues can be deduced based on the mass balance analysis of the initial blood drug. With the estimated rate constants, the drug efflux from tissues into blood was calculated according to equation: OF T-B (efflux from tissues)‫؍‬OF B-U (blood hydrolysis fraction)؉OF B-T (influx into tissues)؊D B (hydrolysis in blood). The net flow (influent flux minus effluent flux) represented the drug hydrolysis fraction in tissue. As the result indicated, in human about 20% drug administrated was hydrolyzed in blood and nearly 80% in tissues. The relative hydrolysis fraction indicated that the main hydrolysis site in human body may locate in tissue, which was different to rats.

SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity profiles

“…Therapeutic plasma levels for both compounds were described to reach about 0.2µM 307 [Hiraku et al, 1982;Cao et al, 2008], which is below the antivirally active 308…”

Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19

“…Following a thorough review of the literature, two PK studies in healthy adults with i.v. administration of the same dosages were identified [ 43 44 ]. However, their exposures were different, up to around two-fold, due to a different quantitative method.…”

“…Nafamostat is unstable in plasma and a highly polar drug with few practical methods for its in vivo quantification and only an insufficient number of PK studies with valid nafamostat concentration measurements available [ 43 44 47 ]. In the same context, the recent randomized controlled study exploring safety and PK/pharmacodynamics reported that the majority of patients exhibited undetectable levels of nafamostat [unpublished data].…”

Pharmacokinetics of Nafamostat, a Potent Serine Protease Inhibitor, by a Novel LC-MS/MS Analysis

“…Due to its high polarity and instability, effective extraction of nafamostat from biological fluids with minimized hydrolysis is critical for a successful analysis [ 18 ]. It has been reported that protein precipitation and liquid–liquid extraction with various solvents did not result in good extraction recovery or sensitivity [ 18 , 26 ]. We also tried protein precipitation with acetonitrile or methanol to extract nafamostat from plasma samples, but a significant matrix effect was observed.…”